CN101831411A - 表达插入痘病毒基因组中的同源基因的重组痘病毒 - Google Patents
表达插入痘病毒基因组中的同源基因的重组痘病毒 Download PDFInfo
- Publication number
- CN101831411A CN101831411A CN200910208520A CN200910208520A CN101831411A CN 101831411 A CN101831411 A CN 101831411A CN 200910208520 A CN200910208520 A CN 200910208520A CN 200910208520 A CN200910208520 A CN 200910208520A CN 101831411 A CN101831411 A CN 101831411A
- Authority
- CN
- China
- Prior art keywords
- virus
- sequence
- gene
- recombinant
- recombinant mva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 124
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000013598 vector Substances 0.000 claims abstract description 37
- 229960005486 vaccine Drugs 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims description 123
- 210000004027 cell Anatomy 0.000 claims description 72
- 238000003780 insertion Methods 0.000 claims description 57
- 230000037431 insertion Effects 0.000 claims description 57
- 108020004414 DNA Proteins 0.000 claims description 53
- 241000725619 Dengue virus Species 0.000 claims description 53
- 241000700618 Vaccinia virus Species 0.000 claims description 32
- 238000010276 construction Methods 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 21
- 238000001890 transfection Methods 0.000 claims description 21
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 241000710831 Flavivirus Species 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 35
- 108020005202 Viral DNA Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 17
- 230000028993 immune response Effects 0.000 abstract description 8
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 description 48
- 230000008034 disappearance Effects 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 27
- 101150064860 PRM gene Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 230000033228 biological regulation Effects 0.000 description 16
- 206010012310 Dengue fever Diseases 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 239000013641 positive control Substances 0.000 description 15
- 241000204031 Mycoplasma Species 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 108700008625 Reporter Genes Proteins 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000006801 homologous recombination Effects 0.000 description 12
- 238000002744 homologous recombination Methods 0.000 description 12
- 230000000813 microbial effect Effects 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000009182 swimming Effects 0.000 description 11
- 238000010367 cloning Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241000204003 Mycoplasmatales Species 0.000 description 9
- 208000009714 Severe Dengue Diseases 0.000 description 9
- 241000700647 Variola virus Species 0.000 description 9
- -1 is preferably C Proteins 0.000 description 9
- 229940031348 multivalent vaccine Drugs 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000013600 plasmid vector Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000025729 dengue disease Diseases 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000008521 reorganization Effects 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 108090000992 Transferases Proteins 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 5
- 241000202894 Mycoplasma orale Species 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 102000004357 Transferases Human genes 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229960004927 neomycin Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- 241000193470 Clostridium sporogenes Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 4
- 241000700629 Orthopoxvirus Species 0.000 description 4
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000007195 tryptone soya broth Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000700628 Chordopoxvirinae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 101150062179 II gene Proteins 0.000 description 3
- 101150049281 PRM1 gene Proteins 0.000 description 3
- 241000700625 Poxviridae Species 0.000 description 3
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 3
- 241000587120 Vaccinia virus Ankara Species 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 108091005948 blue fluorescent proteins Proteins 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000009871 tenuigenin Substances 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000700663 Avipoxvirus Species 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000700572 Entomopoxvirinae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 101150106023 PRM2 gene Proteins 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 208000005585 Poxviridae Infections Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 101150099105 alien gene Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 1
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001569977 Penguinpox virus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101150058724 Prm3 gene Proteins 0.000 description 1
- 101710099276 Probable metalloendopeptidase Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229940023605 dengue virus vaccine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 101150111412 npt gene Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200752 | 2002-05-16 | ||
| DKPA200200753 | 2002-05-16 | ||
| DKPA200200753 | 2002-05-16 | ||
| DKPA200200752 | 2002-05-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN038111063A Division CN1653183B (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101831411A true CN101831411A (zh) | 2010-09-15 |
Family
ID=29551228
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038111225A Expired - Lifetime CN100494388C (zh) | 2002-05-16 | 2003-05-14 | 改进的安卡拉痘苗病毒(mva)基因组中作为插入位点的基因间隔区 |
| CN038111063A Expired - Lifetime CN1653183B (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN2012101928085A Pending CN102703393A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN2012101926963A Pending CN102719408A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN200910208520A Pending CN101831411A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN2011100588236A Pending CN102199628A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038111225A Expired - Lifetime CN100494388C (zh) | 2002-05-16 | 2003-05-14 | 改进的安卡拉痘苗病毒(mva)基因组中作为插入位点的基因间隔区 |
| CN038111063A Expired - Lifetime CN1653183B (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN2012101928085A Pending CN102703393A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| CN2012101926963A Pending CN102719408A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100588236A Pending CN102199628A (zh) | 2002-05-16 | 2003-05-14 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
Country Status (22)
| Country | Link |
|---|---|
| US (14) | US7338662B2 (enExample) |
| EP (3) | EP2253709B1 (enExample) |
| JP (4) | JP4895505B2 (enExample) |
| KR (4) | KR101005630B1 (enExample) |
| CN (6) | CN100494388C (enExample) |
| AT (1) | ATE315660T1 (enExample) |
| AU (4) | AU2003242540A1 (enExample) |
| BR (2) | BRPI0311178B8 (enExample) |
| CA (3) | CA2481799C (enExample) |
| DE (1) | DE60303218T2 (enExample) |
| DK (2) | DK1506301T3 (enExample) |
| EA (3) | EA007811B1 (enExample) |
| ES (1) | ES2256776T3 (enExample) |
| IL (4) | IL164177A0 (enExample) |
| MX (2) | MXPA04010713A (enExample) |
| NO (3) | NO334273B1 (enExample) |
| NZ (2) | NZ536501A (enExample) |
| PL (2) | PL218318B1 (enExample) |
| PT (1) | PT1407033E (enExample) |
| SI (1) | SI1407033T1 (enExample) |
| UA (1) | UA82479C2 (enExample) |
| WO (2) | WO2003097846A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071592A (zh) * | 2016-01-08 | 2018-12-21 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4101327C1 (enExample) * | 1991-01-18 | 1991-10-24 | Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De | |
| UA76731C2 (uk) * | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| WO2003088994A2 (en) * | 2002-04-19 | 2003-10-30 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| DK1506301T3 (da) | 2002-05-16 | 2014-07-21 | Bavarian Nordic As | Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| ES2305514T5 (es) * | 2002-09-05 | 2019-06-14 | Bavarian Nordic As | Método para la amplificación de un poxvirus en condiciones exentas de suero |
| US7638134B2 (en) | 2003-02-20 | 2009-12-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Insertion sites in fowlpox vectors |
| GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
| EP1807508A4 (en) * | 2004-11-05 | 2008-03-12 | Us Gov Health & Human Serv | METHODS FOR PREPARING CELLS AND VIRUSES |
| SI1855720T2 (sl) | 2005-02-23 | 2023-07-31 | Bavarian Nordic A/S | Uporaba modificiranega poksvirusa za hitro indukcijo imunosti proti poksvirusu ali drugim povzročiteljem infekcij |
| US8741633B2 (en) * | 2006-05-19 | 2014-06-03 | Glycofi, Inc. | Recombinant vectors |
| US9133478B2 (en) | 2006-08-25 | 2015-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| US8241638B2 (en) * | 2006-11-09 | 2012-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| EP2390340A3 (en) * | 2007-01-30 | 2012-02-22 | Transgene SA | vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| RU2462513C2 (ru) * | 2007-05-15 | 2012-09-27 | Трансген С.А. | Векторы для множественной генной экспрессии |
| CN101849013A (zh) * | 2007-05-30 | 2010-09-29 | 惠氏有限责任公司 | 猫抗原的浣熊痘病毒表达基因 |
| TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| DK2207564T3 (en) * | 2007-10-18 | 2017-01-16 | Bavarian Nordic As | USE OF VAT FOR TREATMENT OF PROSTATACANCES |
| EP2303322A1 (en) * | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
| KR100894430B1 (ko) * | 2008-11-11 | 2009-04-22 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
| US8999637B2 (en) * | 2008-11-21 | 2015-04-07 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| US20120135032A1 (en) | 2009-10-08 | 2012-05-31 | Bavarian Nordic A/S | Generation of a broad t-cell response in humans against hiv |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
| CA2793772A1 (en) * | 2010-03-26 | 2011-09-29 | Emergent Product Development Gaithersburg Inc. | Ectodomains of influenza matrix 2 protein, expression system, and uses thereof |
| WO2012010280A1 (en) | 2010-07-20 | 2012-01-26 | Bavarian Nordic A/S | Method for harvesting expression products |
| US20120328649A1 (en) * | 2010-09-23 | 2012-12-27 | Baxter Healthcare S.A. | Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus |
| US9173933B2 (en) | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| CA2836299A1 (en) | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| KR20150021088A (ko) | 2012-06-05 | 2015-02-27 | 디 오스트레일리언 내셔널 유니버시티 | 인터루킨-4 길항제를 이용한 백신접종 |
| EA201891945A3 (ru) | 2012-08-01 | 2019-05-31 | Бавариан Нордик А/С | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| AU2013331328B2 (en) | 2012-10-19 | 2018-05-31 | Bavarian Nordic A/S | Methods and compositions for the treatment of cancer |
| US11173206B2 (en) * | 2013-03-15 | 2021-11-16 | Sementis Limited | Immune modulation |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac１０３ 유래의 재조합 백시니아 바이러스 |
| KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac１０３ |
| JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| CA2982896A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan Kettering Cancer Center | Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| CA2987159A1 (en) * | 2015-06-15 | 2016-12-22 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| DK3407910T3 (da) | 2016-01-29 | 2022-07-18 | Bavarian Nordic As | Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus |
| US20190030157A1 (en) * | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| SG11201807022XA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN116440176A (zh) | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| JP2019528271A (ja) * | 2016-08-19 | 2019-10-10 | セメンティス リミテッド | ウイルスワクチン |
| US20200024610A1 (en) * | 2016-09-30 | 2020-01-23 | Monsanto Technology Llc | Method for selecting target sites for site-specific genome modification in plants |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| CA3066573A1 (en) * | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| CN112512568A (zh) | 2018-05-11 | 2021-03-16 | 希望之城 | 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法 |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| WO2020056424A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN111979204B (zh) * | 2019-05-24 | 2023-10-13 | 杭州功楚生物科技有限公司 | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20210299245A1 (en) * | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| EP4288076A4 (en) | 2021-02-02 | 2025-01-22 | Geovax, Inc. | VIRAL CONSTRUCTS FOR USE IN ENHANCING T CELL PRIMING DURING VACCINATION |
| JP2025522951A (ja) | 2022-07-08 | 2025-07-17 | ヴァイロミスル インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよび組換えウイルスならびにその使用方法 |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| US6893845B1 (en) * | 1990-09-28 | 2005-05-17 | Applied Molecular Evolution, Inc. | Surface expression libraries of heteromeric receptors |
| ATE247163T1 (de) * | 1991-03-07 | 2003-08-15 | Virogenetics Corp | Gentechnologisch hergestellter stamm für impfstoffe |
| BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
| FR2679249B1 (fr) * | 1991-07-15 | 1993-11-26 | Centre Nal Recherc Scientifique | Souches de levure avec integration stable de genes heterologues. |
| WO1993003145A1 (en) | 1991-07-26 | 1993-02-18 | Virogenetics Corporation | Infectious bursal disease virus recombinant poxvirus vaccine |
| EP0561034B1 (en) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direct molecular cloning of a modified chordopox virus genome |
| DE69133333T2 (de) | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| EP0753581A1 (en) * | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| DE19629828A1 (de) * | 1996-07-24 | 1998-01-29 | Bayer Ag | Carbanilide |
| US6869793B2 (en) * | 1996-09-24 | 2005-03-22 | Bavarian Nordic Research Institute | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6252871B1 (en) | 1998-07-01 | 2001-06-26 | Powerwave Technologies, Inc. | Switchable combiner/splitter |
| US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| CA2372709C (en) * | 1999-05-28 | 2011-10-25 | Stefan Wintersperger | Vector for integration of heterologous sequences into poxviral genomes |
| WO2001068820A1 (en) * | 2000-03-14 | 2001-09-20 | Anton Mayr | Altered strain of the modified vaccinia virus ankara (mva) |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| EP1326990B1 (en) * | 2000-08-29 | 2007-09-19 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| DK1506301T3 (da) * | 2002-05-16 | 2014-07-21 | Bavarian Nordic As | Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet |
| UA85379C2 (ru) * | 2002-11-25 | 2009-01-26 | Бавариан Нордик А/С | Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы |
-
2003
- 2003-05-14 DK DK03735384T patent/DK1506301T3/da active
- 2003-05-14 EA EA200401507A patent/EA007811B1/ru not_active IP Right Cessation
- 2003-05-14 EP EP10008120.7A patent/EP2253709B1/en not_active Expired - Lifetime
- 2003-05-14 CN CNB038111225A patent/CN100494388C/zh not_active Expired - Lifetime
- 2003-05-14 CN CN038111063A patent/CN1653183B/zh not_active Expired - Lifetime
- 2003-05-14 ES ES03752741T patent/ES2256776T3/es not_active Expired - Lifetime
- 2003-05-14 IL IL16417703A patent/IL164177A0/xx active IP Right Grant
- 2003-05-14 KR KR1020047018293A patent/KR101005630B1/ko not_active Expired - Lifetime
- 2003-05-14 CN CN2012101928085A patent/CN102703393A/zh active Pending
- 2003-05-14 CA CA2481799A patent/CA2481799C/en not_active Expired - Lifetime
- 2003-05-14 CN CN2012101926963A patent/CN102719408A/zh active Pending
- 2003-05-14 BR BRPI0311178A patent/BRPI0311178B8/pt not_active IP Right Cessation
- 2003-05-14 EP EP20030735384 patent/EP1506301B1/en not_active Expired - Lifetime
- 2003-05-14 KR KR1020117031095A patent/KR20120002627A/ko not_active Withdrawn
- 2003-05-14 PL PL372088A patent/PL218318B1/pl unknown
- 2003-05-14 SI SI200330215T patent/SI1407033T1/sl unknown
- 2003-05-14 DE DE2003603218 patent/DE60303218T2/de not_active Expired - Lifetime
- 2003-05-14 CA CA2481521A patent/CA2481521C/en not_active Expired - Lifetime
- 2003-05-14 EA EA200900180A patent/EA020230B1/ru not_active IP Right Cessation
- 2003-05-14 MX MXPA04010713A patent/MXPA04010713A/es active IP Right Grant
- 2003-05-14 AT AT03752741T patent/ATE315660T1/de active
- 2003-05-14 PT PT03752741T patent/PT1407033E/pt unknown
- 2003-05-14 IL IL16417203A patent/IL164172A0/xx unknown
- 2003-05-14 CN CN200910208520A patent/CN101831411A/zh active Pending
- 2003-05-14 KR KR1020047018165A patent/KR101041691B1/ko not_active Expired - Lifetime
- 2003-05-14 EP EP20030752741 patent/EP1407033B1/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003242540A patent/AU2003242540A1/en not_active Abandoned
- 2003-05-14 WO PCT/EP2003/005047 patent/WO2003097846A1/en not_active Ceased
- 2003-05-14 EA EA200401506A patent/EA012160B1/ru not_active IP Right Cessation
- 2003-05-14 PL PL372093A patent/PL216760B1/pl unknown
- 2003-05-14 BR BR0310051A patent/BR0310051A/pt not_active IP Right Cessation
- 2003-05-14 JP JP2004506500A patent/JP4895505B2/ja not_active Expired - Lifetime
- 2003-05-14 US US10/510,189 patent/US7338662B2/en not_active Expired - Lifetime
- 2003-05-14 DK DK03752741T patent/DK1407033T3/da active
- 2003-05-14 UA UA20041109409A patent/UA82479C2/uk unknown
- 2003-05-14 JP JP2004506501A patent/JP4693092B2/ja not_active Expired - Lifetime
- 2003-05-14 KR KR1020107021891A patent/KR101138067B1/ko not_active Expired - Lifetime
- 2003-05-14 CA CA 2812019 patent/CA2812019A1/en not_active Abandoned
- 2003-05-14 AU AU2003236646A patent/AU2003236646B2/en not_active Expired
- 2003-05-14 WO PCT/EP2003/005045 patent/WO2003097845A1/en not_active Ceased
- 2003-05-14 NZ NZ536501A patent/NZ536501A/en not_active IP Right Cessation
- 2003-05-14 CN CN2011100588236A patent/CN102199628A/zh active Pending
- 2003-05-14 US US10/514,761 patent/US7550147B2/en not_active Expired - Lifetime
- 2003-05-14 NZ NZ536502A patent/NZ536502A/en not_active IP Right Cessation
- 2003-05-14 MX MXPA04011194A patent/MXPA04011194A/es active IP Right Grant
-
2004
- 2004-11-12 NO NO20044940A patent/NO334273B1/no not_active IP Right Cessation
- 2004-12-16 NO NO20045480A patent/NO336489B1/no not_active IP Right Cessation
-
2007
- 2007-11-15 US US11/985,510 patent/US9109233B2/en active Active
-
2008
- 2008-07-28 IL IL193087A patent/IL193087A/en active IP Right Grant
- 2008-07-28 IL IL19308808A patent/IL193088A/en active IP Right Grant
- 2008-12-09 AU AU2008255213A patent/AU2008255213B2/en not_active Expired
- 2008-12-19 US US12/339,743 patent/US20100173388A1/en not_active Abandoned
-
2009
- 2009-02-03 AU AU2009200380A patent/AU2009200380C1/en not_active Expired
- 2009-05-19 US US12/468,127 patent/US8034354B2/en not_active Expired - Lifetime
- 2009-05-19 US US12/468,120 patent/US7964374B2/en not_active Expired - Lifetime
-
2010
- 2010-08-05 JP JP2010176512A patent/JP5777199B2/ja not_active Expired - Lifetime
- 2010-08-05 JP JP2010176511A patent/JP2011004755A/ja active Pending
- 2010-09-30 US US12/894,550 patent/US20110053259A1/en not_active Abandoned
- 2010-09-30 US US12/894,589 patent/US20110053260A1/en not_active Abandoned
-
2011
- 2011-04-15 US US13/087,715 patent/US8288125B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,649 patent/US8309326B2/en not_active Expired - Fee Related
- 2011-09-15 US US13/233,329 patent/US8414900B2/en not_active Expired - Fee Related
- 2011-09-16 US US13/234,230 patent/US8435543B2/en not_active Expired - Fee Related
- 2011-09-29 NO NO20111324A patent/NO20111324A1/no not_active Application Discontinuation
-
2012
- 2012-02-13 US US13/371,580 patent/US20120178157A1/en not_active Abandoned
-
2013
- 2013-05-02 US US13/886,093 patent/US8741308B2/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071592A (zh) * | 2016-01-08 | 2018-12-21 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| CN109071592B (zh) * | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101831411A (zh) | 表达插入痘病毒基因组中的同源基因的重组痘病毒 | |
| US8623381B2 (en) | Viral strains derived from the vaccinia virus Lister VACV-107 and uses thereof | |
| MXPA04011034A (es) | Expresion de los genes en el virus de la vacuna de ankara modificada, usando el promotor ati de viruela. | |
| HK1076642B (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1144700A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1156979A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1170772A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1171249A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1144700 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100915 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1144700 Country of ref document: HK |